One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment

Affiliation auteursAffiliation ok
TitreOne-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment
Type de publicationJournal Article
Year of Publication2017
AuteursPivot X., Bondarenko I.M, Nowecki Z., Dvorkin M., Trishkina E., Ahn J.H, Vinnyk Y., Im S-A., Sarosiek T., Chatterjee S., Wojtukiewicz M., Moiseyenko V., Shparyk Y., , Semiglazov V., Younju L., Lim J.
JournalANNALS OF ONCOLOGY
Volume28
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534